Onyx begins Phase I trials of Onyx-015 adenovirus for p53-deficient tumors -- IPO prospectus.
Executive Summary
ONYX COMMENCES PHASE I TRIALS OF ONYX-015 FOR p53-DEFICIENT TUMORS, the company discloses in its initial public offering prospectus. Trials of the genetically engineered adenovirus began in the U.S. and U.K. in April and will enroll patients with p53-deficient tumors of the head and neck. Preclinical development is ongoing in p53-deficient ovarian, liver and other cancers.